Myconostica Ltd develops and supplies molecular diagnostic products to aid speedy, accurate diagnosis of life-threatening fungal infections in humans.
All developed countries have recorded steep increases in these blood-stream, respiratory and brain infections. Under-diagnosis and slow diagnosis with current methods available contribute to a high death rate. With recent advances in genomics and Real-Time PCR technology, rapid molecular testing is now possible and highly desirable and can transform the ability of medics to save both patients' lives and significant expenditure on hospitalization and drug treatment. |
|
|
